Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUGAR: Darolutamide + Surgery in High-Risk Prostate Cancer
NCT05826509Phase 2Active, not recruiting
- Sponsor
- Institut Claudius Regaud
- Start
- Aug 2023
- Primary completion
- Feb 2031
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Institut Claudius Regaud. Primary endpoint: Non-curable progression-free survival at 5 years. Started Aug 2023; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05826509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826509.